Business Context and Reporting Period
This Form 8-K Current Report from Vanda Pharmaceuticals Inc. (VNDA) covers the period ending March 29, 2026, with the report filed on April 2, 2026. The filing addresses a material corporate governance event involving the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the resignation of Timothy Williams, who served as Senior Vice President, General Counsel, and Secretary. His resignation is effective as of April 10, 2026, to pursue other endeavors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies related to the resignation are detailed beyond the standard disclosure of the departure.
Investor Verification Checklist
- Confirm the effective date of Timothy Williams' resignation (April 10, 2026).
- Verify if a successor has been appointed for the roles of Senior Vice President, General Counsel, and Secretary.
- Check for any concurrent filings regarding the transition of legal and corporate governance responsibilities.